Abstract
Background Reward dysfunction has been implicated in many psychiatric disorders such as attention-deficit/hyperactivity disorders, depression, and substance use disorders. However, psychiatric comorbidities are common, and the specificity of reward dysfunction to individual psychopathologies is unknown. The objective of this study was to evaluate the association between reward functioning and specific or general psychopathologies.
Methods 1044 adults and their 1215 children (ages 6-12) completed various measures of the Positive Valence System domain from the Research Domain Criteria (RDoC), which included the Delayed and Probability Discounting Tasks, Energy Expenditure for Reward Task, and Iowa Gambling Task. Children also completed the Experienced Pleasure Scale for children, while adults completed the Temporal Experience of Pleasure Scale and the Behavioral Activation System tasks. Psychopathology was assessed using the Child Behavior Checklist (CBCL) for children and the Adult Self Report (ASR) for parents.
Results One general factor identified via principal factors factor analysis explained the majority of variance in psychopathology in both groups. Reward measures in both adults and children were significantly associated with general psychopathology as well as most specific psychopathologies. Some associations between reward and psychopathology did not hold following removal of general psychopathology; nonetheless, certain reward constructs were uniquely associated with specific disorder problems but not general psychopathology.
Conclusion Disorder problem specific associations with reward functioning can be identified after removal of comorbidity. General propensity toward psychopathology is significantly but not uniquely correlated with reward dysfunction. Altogether, this may have broader implications for future study of the role of reward in disease pathogenesis.
Competing Interest Statement
Within the last year, Dr. Faraone received income, potential income, travel expenses, continuing education support, and/or research support from Akili, Arbor, Genomind, Ironshore, KemPharm/Corium, Ondosis, Otsuka, Rhodes, Shire/Takeda, Supernus, and Tris. With his institution, he holds US patent US20130217707 A1 for the use of sodium-hydrogen exchange inhibitors in ADHD treatment. Previously, he received support from: Alcobra, Aveksham, CogCubed, Eli Lilly, Enzymotec, Impact, Janssen, Lundbeck/Takeda, McNeil, NeuroLife Sciences, Neurovance, Novartis, Pfizer, Sunovion, and Vallon. He also receives royalties from books published by Guilford Press: Straight Talk about Your Child`s Mental Health; Oxford University Press: Schizophrenia: The Facts; and Elsevier: ADHD: Non-Pharmacologic interventions. In addition, he is the program director of www.adhdinadults.com. Authors Ankita Saxena, Catharina A. Hartman, Steven D. Blatt, Wanda P. Fremont, Stephen J. Glatt, and Yanli Zhang-James declare no Conflict of Interest or Financial Disclosures.
Funding Statement
This project has received funding from the European Union`s Horizon 2020 research and innovation programme for the CoCa project under grant agreement No. 667302 and NIMH grants R01MH101519-01A1 and R01MH101519-01A1S1. This report reflects only the views of the authors and the commission bears no responsibility for any uses made of the information contained in the report.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The IRB of SUNY Upstate Medical University gave ethical approval of this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors and institutional approval
